Rishad Khan, Kayley-Jasmin Marchena-Romero, Marwa F Ismail, Surain B Roberts, Nikko Gimpaya, Michael A Scaffidi, Nasruddin Sabrie, Kareem Khalaf, Jeffrey Mosko, Paul James, Nauzer Forbes, Fahad Razak, Amol A Verma, Samir C Grover
{"title":"现场ERCP可用性与胆管炎结局:回顾性队列研究。","authors":"Rishad Khan, Kayley-Jasmin Marchena-Romero, Marwa F Ismail, Surain B Roberts, Nikko Gimpaya, Michael A Scaffidi, Nasruddin Sabrie, Kareem Khalaf, Jeffrey Mosko, Paul James, Nauzer Forbes, Fahad Razak, Amol A Verma, Samir C Grover","doi":"10.1055/a-2494-7333","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and study aims: </strong>Endoscopic retrograde cholangiopancreatography (ERCP) is important in acute cholangitis (AC) management but is not available at all hospitals. The association between on-site ERCP availability and cholangitis outcomes is unknown.</p><p><strong>Patients and methods: </strong>We included adults diagnosed with AC at 27 hospitals in Ontario through the GEMINI network. We collected data on demographics, clinical and laboratory values, and interventions. The primary outcome was in-hospital mortality. Secondary outcomes were length of stay, intensive care unit (ICU) admission, readmission rates, and requirement for percutaneous or surgical decompression. We used multivariable regression analyses to assess the impact of on-site ERCP availability on the primary and secondary outcomes with adjustment for relevant variables.</p><p><strong>Results: </strong>Our cohort included 4492 patients with a median age of 75. Patients at ERCP sites had higher unadjusted rates of undergoing ERCP (55.7% at ERCP sites, 40.8% at non-ERCP sites). Patients at ERCP sites compared with non-ERCP sites did not have significantly different in-hospital mortality (adjusted odds ratio [aOR] = 2.19, 95% confidence interval [CI] = 0.86-5.55). Compared with non-ERCP sites, patients at ERCP sites with underlying stricturing biliary disease or pancreaticobiliary malignancy (aOR = 1.94, 95% CI = 1.14-13.58) or severe cholangitis (aOR = 2.17, 95% CI = 1.17-4.02) had higher odds of in-hospital mortality. In a post-hoc propensity score-based analysis, there was no significant difference between patients at ERCP sites compared with those at non-ERCP sites for in-hospital mortality.</p><p><strong>Conclusions: </strong>Patients at ERCP sites compared with non-ERCP sites did not have significantly different mortality. Subgroups of patients with underlying stricturing biliary disease or pancreaticobiliary malignancy and severe cholangitis, who have higher mortality at ERCP sites, warrant further study.</p>","PeriodicalId":11671,"journal":{"name":"Endoscopy International Open","volume":"13 ","pages":"a24947333"},"PeriodicalIF":2.2000,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11827753/pdf/","citationCount":"0","resultStr":"{\"title\":\"On-site ERCP availability and cholangitis outcomes: Retrospective cohort study.\",\"authors\":\"Rishad Khan, Kayley-Jasmin Marchena-Romero, Marwa F Ismail, Surain B Roberts, Nikko Gimpaya, Michael A Scaffidi, Nasruddin Sabrie, Kareem Khalaf, Jeffrey Mosko, Paul James, Nauzer Forbes, Fahad Razak, Amol A Verma, Samir C Grover\",\"doi\":\"10.1055/a-2494-7333\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background and study aims: </strong>Endoscopic retrograde cholangiopancreatography (ERCP) is important in acute cholangitis (AC) management but is not available at all hospitals. The association between on-site ERCP availability and cholangitis outcomes is unknown.</p><p><strong>Patients and methods: </strong>We included adults diagnosed with AC at 27 hospitals in Ontario through the GEMINI network. We collected data on demographics, clinical and laboratory values, and interventions. The primary outcome was in-hospital mortality. Secondary outcomes were length of stay, intensive care unit (ICU) admission, readmission rates, and requirement for percutaneous or surgical decompression. We used multivariable regression analyses to assess the impact of on-site ERCP availability on the primary and secondary outcomes with adjustment for relevant variables.</p><p><strong>Results: </strong>Our cohort included 4492 patients with a median age of 75. Patients at ERCP sites had higher unadjusted rates of undergoing ERCP (55.7% at ERCP sites, 40.8% at non-ERCP sites). Patients at ERCP sites compared with non-ERCP sites did not have significantly different in-hospital mortality (adjusted odds ratio [aOR] = 2.19, 95% confidence interval [CI] = 0.86-5.55). Compared with non-ERCP sites, patients at ERCP sites with underlying stricturing biliary disease or pancreaticobiliary malignancy (aOR = 1.94, 95% CI = 1.14-13.58) or severe cholangitis (aOR = 2.17, 95% CI = 1.17-4.02) had higher odds of in-hospital mortality. In a post-hoc propensity score-based analysis, there was no significant difference between patients at ERCP sites compared with those at non-ERCP sites for in-hospital mortality.</p><p><strong>Conclusions: </strong>Patients at ERCP sites compared with non-ERCP sites did not have significantly different mortality. Subgroups of patients with underlying stricturing biliary disease or pancreaticobiliary malignancy and severe cholangitis, who have higher mortality at ERCP sites, warrant further study.</p>\",\"PeriodicalId\":11671,\"journal\":{\"name\":\"Endoscopy International Open\",\"volume\":\"13 \",\"pages\":\"a24947333\"},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2025-01-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11827753/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Endoscopy International Open\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1055/a-2494-7333\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Endoscopy International Open","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1055/a-2494-7333","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景和研究目的:内镜逆行胆管造影术(ERCP)在急性胆管炎(AC)治疗中很重要,但并非所有医院都有。现场ERCP可用性与胆管炎结局之间的关系尚不清楚。患者和方法:我们通过GEMINI网络纳入了安大略省27家医院诊断为AC的成年人。我们收集了人口统计学、临床和实验室价值以及干预措施方面的数据。主要终点是住院死亡率。次要结果为住院时间、重症监护病房(ICU)入院、再入院率和经皮或手术减压的要求。我们使用多变量回归分析来评估现场ERCP可用性对主要和次要结局的影响,并对相关变量进行调整。结果:我们的队列包括4492例患者,中位年龄为75岁。ERCP部位的患者接受ERCP的未调整率更高(ERCP部位55.7%,非ERCP部位40.8%)。发生ERCP的患者与未发生ERCP的患者相比,住院死亡率无显著差异(校正优势比[aOR] = 2.19, 95%可信区间[CI] = 0.86-5.55)。与非ERCP部位相比,ERCP部位合并基础狭窄性胆道疾病或胰胆道恶性肿瘤(aOR = 1.94, 95% CI = 1.14-13.58)或严重胆管炎(aOR = 2.17, 95% CI = 1.17-4.02)的患者住院死亡率更高。在一项基于事后倾向评分的分析中,ERCP站点的患者与非ERCP站点的患者在住院死亡率方面没有显著差异。结论:发生ERCP部位的患者与非ERCP部位的患者死亡率无显著差异。潜在狭窄性胆道疾病或胰胆管恶性肿瘤和严重胆管炎患者亚组在ERCP部位有较高的死亡率,值得进一步研究。
On-site ERCP availability and cholangitis outcomes: Retrospective cohort study.
Background and study aims: Endoscopic retrograde cholangiopancreatography (ERCP) is important in acute cholangitis (AC) management but is not available at all hospitals. The association between on-site ERCP availability and cholangitis outcomes is unknown.
Patients and methods: We included adults diagnosed with AC at 27 hospitals in Ontario through the GEMINI network. We collected data on demographics, clinical and laboratory values, and interventions. The primary outcome was in-hospital mortality. Secondary outcomes were length of stay, intensive care unit (ICU) admission, readmission rates, and requirement for percutaneous or surgical decompression. We used multivariable regression analyses to assess the impact of on-site ERCP availability on the primary and secondary outcomes with adjustment for relevant variables.
Results: Our cohort included 4492 patients with a median age of 75. Patients at ERCP sites had higher unadjusted rates of undergoing ERCP (55.7% at ERCP sites, 40.8% at non-ERCP sites). Patients at ERCP sites compared with non-ERCP sites did not have significantly different in-hospital mortality (adjusted odds ratio [aOR] = 2.19, 95% confidence interval [CI] = 0.86-5.55). Compared with non-ERCP sites, patients at ERCP sites with underlying stricturing biliary disease or pancreaticobiliary malignancy (aOR = 1.94, 95% CI = 1.14-13.58) or severe cholangitis (aOR = 2.17, 95% CI = 1.17-4.02) had higher odds of in-hospital mortality. In a post-hoc propensity score-based analysis, there was no significant difference between patients at ERCP sites compared with those at non-ERCP sites for in-hospital mortality.
Conclusions: Patients at ERCP sites compared with non-ERCP sites did not have significantly different mortality. Subgroups of patients with underlying stricturing biliary disease or pancreaticobiliary malignancy and severe cholangitis, who have higher mortality at ERCP sites, warrant further study.